Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel

被引:17
作者
Rennert, G [1 ]
Dishon, S
Rennert, HS
Fares, F
机构
[1] Carmel Hosp, CHS Natl Canc Control Ctr, CHS Natl Familial Canc Consultat Serv, IL-34362 Haifa, Israel
[2] Technion Israel Inst Technol, Fac Med, IL-34362 Haifa, Israel
[3] Carmel Hosp, Biochem Lab, Genet Unit, Haifa, Israel
关键词
BRCA; gene mutations; Israel; Ashkenazi Jews;
D O I
10.1097/00008469-200508000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Three specific mutations in the BRCA1 (185delAG, 5382insC) and BRCA2 (6174deIT) genes have been reported to be of high prevalence in the Jewish Ashkenazi population. We studied the differences in phenotype of families carrying these mutations. All consecutive families found by the CHS Familial Cancer Service to carry one of the three ' Jewish ' mutations of the BRCA1/BRCA2 genes were evaluated for phenotypic characteristics. Chi-squared and Student ' s t-test statistics were employed to study differences in a variety of clinical and demographic parameters. A total of 111 families with 1499 family members were included. Among them 454 cases of cancer (297 in breast/ovary) were reported. Ovarian cancer, but not breast cancer, was detected at a significantly younger age among carriers of 185delT compared with other mutation carriers. In families with 185delAG, 5382insC and 6174delT mutations, breast cancer was found in 20.2, 39.4 and 24.1% of all identified women (born between 1900 and 1975), correspondingly. The corresponding figures for ovarian cancer were 13.9, 6.8 and 4.9%. Families carrying the 5382insC mutation had the highest probability of expressing bilateral breast cancer (38.9% of families, 15.4% of women with cancer, 6.1% of all women in family) and metachronous breast and ovary tumours (22.2, 9.8 and 4.5% correspondingly). Other tumours were reported in 7.9, 9.1 and 12.0% of women and 9.5,12.9 and 15.8% of men in families with 186delAG, 5382insC, 6174delT, correspondingly. Marked phenotypic differences were found between families carrying different BRCA mutations warranting mutation-specific counselling to families seeking risk-reduction advice. 5382insC emerged as a most aggressive mutation. European Journal of Cancer Prevention 14:357-361 (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:357 / 361
页数:5
相关论文
共 23 条
[1]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[2]  
Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741
[3]  
LevyLahad E, 1997, AM J HUM GENET, V60, P1059
[4]   A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].
MIKI, Y ;
SWENSEN, J ;
SHATTUCKEIDENS, D ;
FUTREAL, PA ;
HARSHMAN, K ;
TAVTIGIAN, S ;
LIU, QY ;
COCHRAN, C ;
BENNETT, LM ;
DING, W ;
BELL, R ;
ROSENTHAL, J ;
HUSSEY, C ;
TRAN, T ;
MCCLURE, M ;
FRYE, C ;
HATTIER, T ;
PHELPS, R ;
HAUGENSTRANO, A ;
KATCHER, H ;
YAKUMO, K ;
GHOLAMI, Z ;
SHAFFER, D ;
STONE, S ;
BAYER, S ;
WRAY, C ;
BOGDEN, R ;
DAYANANTH, P ;
WARD, J ;
TONIN, P ;
NAROD, S ;
BRISTOW, PK ;
NORRIS, FH ;
HELVERING, L ;
MORRISON, P ;
ROSTECK, P ;
LAI, M ;
BARRETT, JC ;
LEWIS, C ;
NEUHAUSEN, S ;
CANNONALBRIGHT, L ;
GOLDGAR, D ;
WISEMAN, R ;
KAMB, A ;
SKOLNICK, MH .
SCIENCE, 1994, 266 (5182) :66-71
[5]  
*MIN HLTH ISR, 1997, ISR CANC REG
[6]   The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% [J].
Oddoux, C ;
Struewing, JP ;
Clayton, CM ;
Neuhausen, S ;
Brody, LC ;
Kaback, M ;
Haas, B ;
Norton, L ;
Borgen, P ;
Jhanwar, S ;
Goldgar, D ;
Ostrer, H ;
Offit, K .
NATURE GENETICS, 1996, 14 (02) :188-190
[7]  
Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt
[8]  
827::AID-IJC6&gt
[9]  
3.0.CO
[10]  
2-P